New combo for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (metastatic) or locally advanced pancreatic cancer that cannot be removed by surgery.
- You have had either no prior chemotherapy, or only one type of chemotherapy (targeted therapies alone don't count).
- You are in generally good health (able to do daily activities with little or no help).
- You have a tumor that can be seen on scans (CT or MRI).
- You have not had immunotherapy (checkpoint inhibitors) before, unless you are in a specific part of this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ONT01 combined with two standard chemo drugs (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that has spread and is no longer responding to first treatment. The goal is to see if this new combination can help control the cancer.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
This trial tests a new targeted drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for people with advanced pancreatic cancer that has spread. The goal is to see if this combination works better than current treatments.
This trial tests a combination of three drugs (gemcitabine, erlotinib, and nab-paclitaxel) for people with a specific type of pancreatic cancer called 'basal-like' PDAC. It aims to see if this targeted approach works better than standard treatment.
This trial tests a new combination of drugs (chiauranib, a PD-1 inhibitor, and two chemotherapy drugs) for people with a specific type of advanced pancreatic cancer who have not had prior treatment. It aims to see if this combination can help shrink tumors and improve outcomes.
Hear when a new Pancreatic Adenocarcinoma Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.